Rhodiola rosea L. — A comprehensive evidence-based clinical monograph covering adaptogenic, antidepressant, antifatigue, neuroprotective, immunostimulant and anticancer pharmacology. EMA-approved herbal medicine standardised to salidroside and rosavins.
Rhodiola rosea L. — the "golden root" — is the most extensively studied adaptogen in European phytomedicine, officially recognised by the EMA (European Medicines Agency) in a revised herbal monograph (2024). Its primary pharmacological spectrum spans adaptogenic, antifatigue, antidepressant, anxiolytic, neuroprotective, immunostimulant and anti-ageing activity, mediated chiefly through salidroside, rosavins and their modulation of monoamine systems, HSP70 and neuropeptide Y. Its immunostimulant potency is comparable to ginseng.
Rhodiola rosea is a mountain plant of cold Arctic and sub-Arctic zones, also found at altitude in temperate regions. It is colloquially called the "tundra ginseng" — a reference to its adaptogenic power comparable to true ginseng. It grows in Russia, Scandinavia, Quebec, and Switzerland (at altitude).
The name rhodiola derives from Latin borrowed from Greek rhodios, referring to the rose scent emitted by the root — an olfactory characteristic that distinguishes it in the field. The rhizome has a thick, fleshy, branching structure typical of the Crassulaceae (stonecrop family).
⚠ Conservation Alert — CITES 2023
Since 2023, Rhodiola rosea is listed on Appendix II of CITES (Convention on International Trade in Endangered Species) for wild-harvested specimens. Always prefer products from cultivated origin. Wild harvesting should be avoided. Related species R. quadrifida (Mongolia) and R. crenulata are also threatened.
Name Origin
The name rhodiola comes from Greek rhodios — referring to the characteristic rose-like fragrance of the fresh root. The English name "golden root" refers to the golden-yellow colour of the dried rhizome cortex.
Rhodiola rosea has a recorded history stretching back to antiquity. Dioscorides cited it in De materia Medica. Under the name "golden root" it has been consumed across Arctic and sub-Arctic cultures as a physical and mental tonic — a tradition now substantiated by modern pharmacology.
Referenced in De materia Medica, one of the most influential pharmacological texts of antiquity — establishing rhodiola's medicinal reputation before the Common Era.
Consumed under the name "golden root" to prevent fatigue and "lack of desire to work" (Ssaratikov, 1968), increase physical endurance, and prevent altitude sickness. Used in Russia, Scandinavia and Iceland for centuries.
Used as an infusion by the Yakuts of Eastern Siberia for its stimulant properties — part of a rich indigenous pharmacopoeial tradition in harsh Arctic conditions.
Inuit communities consumed the fleshy stems and leaves of rhodiola in large quantities as a green vegetable — combining nutritional value with the plant's stimulant and adaptogenic properties.
EMA Recognition 2024
"A single administration of a combination of Eleutherococcus, Schisandra and Rhodiola rosea produces a stimulating effect within 30 minutes, persisting for at least 4–6 hours — without adverse effects."
Panossian 2005 — Ref [11]
The European Medicines Agency issued a revised herbal monograph on Rhodiola rosea rhizome and root in March 2024 (EMA/HMPC/24177/2023), reflecting the most comprehensive regulatory evaluation of this plant in Europe. [1],[2]
Rhodiola rosea's adaptogenic immunostimulant potency (carbon clearance test, 60° alcohol extract) is comparable to that of ginseng — and superior to echinacea in muscle force and spontaneous locomotion in mice.
The rhizome is the sole medicinal part, available in three principal pharmaceutical forms.
The rhizome (root and rhizome) is the pharmacologically active part of the plant. Products must be standardised to salidroside and rosavin content to ensure therapeutic efficacy. Source material from cultivated plants only is recommended — wild-harvested material is covered by CITES Appendix II since 2023.
Hydroalcoholic dry extracts (60–70% v/v) are the principal clinical form — available as Elusanes® and equivalent branded products. This is the form evaluated in the majority of clinical trials and the one addressed by the EMA monograph. Standardised to 3% rosavins and 1% salidroside.
EPS (fresh plant extract, glycerinated) — preserves the full phytochemical spectrum of the fresh root. Powder capsules (Arkogélules®) — convenient oral form. Note: powder forms may be less standardised than dry extracts and pharmacokinetic equivalence with liquid extracts should not be assumed.
The pharmacological activity of rhodiola is driven by a complex phytochemical profile dominated by phenylethanoïds and phenylpropanoïds, with a minor essential oil fraction.
The rose fragrance of the fresh rhizome — which gives rhodiola its name — arises from geraniol and related monoterpenic alcohols. The EO was characterised from three geographic origins (Bulgarian, Ukrainian and Austrian). [4]
Standardisation Markers
Commercial extracts are standardised to 3% rosavins + 1% salidroside — the ratio reflecting the natural proportion in authentic Rhodiola rosea (as opposed to other rhodiola species). Only R. rosea contains rosavins; salidroside alone is not sufficient for species authentication.
Increases non-specific resistance to biological, chemical and physical stressors. [5],[6],[7] Activates release of neuropeptide Y and heat shock proteins (HSP70/HSP72) — the molecular basis of adaptogenic stress-protection. [13],[14],[15] Immunostimulant potency comparable to ginseng.
Major, multi-target antidepressant activity documented in a literature review. [28] Randomised study showed favourable effect on mild to moderate depression. [9] MAO-A inhibition (MAOI-A effect) drives antidepressant activity; MAO-B inhibition has potential in senile dementia. [29] Head-to-head RCT vs. sertraline: favourable tolerability profile. [48]
Evidence-based antifatigue activity documented. [10] A single dose produces a stimulating effect within 30 minutes, persisting 4–6 hours. [11] Increases mental performance and concentration; reduces salivary cortisol response in stress-related fatigue syndrome. [12]
Improves physical performance and muscular resistance (salidroside). [16] Reduces exercise-induced oxidative stress in rats. [17] Increases muscle glycogen content. [18] Effect on muscular force and spontaneous locomotion is close to that of ginseng and superior to echinacea.
Improves mental performance with 10 mg salidroside; salidroside improves cognition and mood disorders. [19] Improves memory, [20],[21],[22] attention and learning; 50% improvement in error tests with total alcoholic extract. Anti-cholinesterase activity. [24]
The combination of Rhodiola rosea + Ginkgo biloba shows more significant effect on cognitive function than either herb used alone. [23]
Stimulates hippocampal cell proliferation; increases cerebral 5-hydroxytryptamine (serotonin). [25],[26] Raises serotonin and dopamine levels by lowering COMT (catechol-O-methyltransferase) — the enzyme that degrades both neurotransmitters. [27]
Pilot RCT demonstrated efficacy in generalised anxiety disorder (GAD). [30] Improves anxiety symptoms and reduces signs of stress and depression. [47] May attenuate adverse effects of antidepressants.
Anti-inflammatory and neuroprotective effects of constituents (rosine, salidroside) demonstrated. [31] Reduces cognitive impairment induced by intracerebroventricular streptozotocin in rats — antioxidant and neuroprotective mechanisms. [32]
Alpha-glucosidase inhibition. [33] Hypoglycaemic effect [34] and antihypoglycaemic effect after insulin addition. Salidroside inhibits hyperglycaemia-induced mesangial cell proliferation — protective in diabetic nephropathy. [35]
Described as a "second-generation adaptogen" with documented anti-inflammatory activity. [36] Inhibits inflammatory pathways relevant to metabolic and systemic inflammatory conditions.
Stimulates T-lymphocyte proliferation. [37] Increases phagocytosis. [38] Stimulates granulocyte activity, increases lymphocyte response and cellular immunity. [39] Note: high doses may induce inhibitory effects. [40]
Neuraminidase inhibitory activity from flavonols isolated from Rhodiola rosea roots — with in vitro anti-influenza viral activity. [41]
Anticancer and anti-angiogenic properties. [42] Antiproliferative and antimitotic effect, S-phase accumulation, induction of apoptosis and necrosis on HL-60 cells. [43] Improves efficacy of cytostatic drugs. [44]
Potential applications in ageing-related diseases. [44] Anti-stress, anti-ageing and immunostimulating properties relevant to cancer chemoprevention. [45]
Evidence-based indications for whole-plant preparations, supported by RCTs, systematic reviews, and the EMA 2024 herbal monograph.
Compound-level mechanisms through which Rhodiola rosea's principal actives exert their pharmacological effects.
Action on the level and activity of monoamines and opioid peptides such as beta-endorphins. MAO-A inhibition drives antidepressant activity. MAO-B inhibition has potential in senile dementia. [29] Raises serotonin and dopamine by lowering COMT (catechol-O-methyltransferase). [27]
Adaptogens activate the release of neuropeptide Y and heat shock protein HSP70 (Hsp72) from neuroglia cells. [13],[14],[15] This represents the molecular stress-protective mechanism common to all true adaptogens and is considered the primary mode of action of rhodiola's adaptogenic activity.
Salidroside (the principal phenylethanoïd) improves cognition and mood, [19] inhibits alpha-glucosidase (antidiabetic), [33] inhibits hyperglycaemia-induced mesangial proliferation, [35] and protects dopaminergic neurons via ROS-NO-related mitochondrial pathways in Parkinson's models. [54]
Review of documented adverse effects, contraindications, and drug interactions based on EMA assessment and clinical literature.